View Older Stories View More Recent Stories
-
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
-
Phio Pharmaceuticals (PHIO) Presenting Data on PH-894
-
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
-
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
-
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
-
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
-
Phio Pharmaceuticals (PHIO) Appoints Robert M. Infarinato as CFO
-
Phio Pharmaceuticals Announces New Chief Financial Officer
-
Phio Pharmaceuticals (PHIO) to Receive $3.1M Gross Proceeds from Warrant Exercise
-
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
-
Phio Pharmaceuticals (PHIO) Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
-
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
-
Phio Pharmaceuticals Corp. (PHIO) Terminates Share Purchase Agreement with Triton Funds
-
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
-
Phio Pharmaceuticals Corp. (PHIO) Announces Reverse Stock Split
-
Phio Pharmaceuticals Announces Reverse Stock Split
-
Phio Pharmaceuticals Corp. (PHIO) Announces New Patent for INTASYL
-
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

